Venture Capital News and Headlines
  • All Technology
  • AI
  • Autonomy
  • B2B Growth
  • Big Data
  • BioTech
  • ClimateTech
  • Consumer Tech
  • Crypto
  • Cybersecurity
  • DevOps
  • Digital Marketing
  • Ecommerce
  • EdTech
  • Enterprise
  • FinTech
  • GovTech
  • Hardware
  • HealthTech
  • HRTech
  • LegalTech
  • Nanotech
  • PropTech
  • Quantum
  • Robotics
  • SaaS
  • SpaceTech
AllNewsDealsSocialBlogsVideosPodcastsDigests

Venture Capital Pulse

EMAIL DIGESTS

Daily

Every morning

Weekly

Sunday recap

NewsDealsSocialBlogsVideosPodcasts
Venture CapitalNewsElephas Biosciences Receives $40M Series B-2
Elephas Biosciences Receives $40M Series B-2
Venture Capital

Elephas Biosciences Receives $40M Series B-2

•November 6, 2025
0
VC News Daily
VC News Daily•Nov 6, 2025

Companies Mentioned

ARCH Venture Partners

ARCH Venture Partners

Northpond Ventures

Northpond Ventures

State of Wisconsin Investment Board

State of Wisconsin Investment Board

Sands Capital

Sands Capital

Why It Matters

The capital infusion accelerates development and commercialization of a technology that could dramatically improve patient selection for immunotherapies, reducing costly trial-and‑error and expanding market adoption. Successful deployment would address a critical gap in oncology, potentially improving outcomes and lowering healthcare costs.

Elephas Biosciences Receives $40M Series B-2

Read Original Article
0

Comments

Want to join the conversation?

Loading comments...